Experienced in Hydatidiform Mole

Dr. James F. Barter

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
6301 Executive Blvd, 
Rockville, MD 
Accepting New Patients
Experienced in Hydatidiform Mole
6301 Executive Blvd, 
Rockville, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Barter is a Gynecologic Oncologist and an Oncologist in Rockville, Maryland. Dr. Barter is rated as an Experienced provider by MediFind in the treatment of Hydatidiform Mole. His top areas of expertise are Ovarian Cysts, Neonatal Ovarian Cyst, Endometrial Cancer, Hysterectomy, and Oophorectomy. Dr. Barter is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

6301 Executive Blvd, Rockville, MD 20852

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

5 Total Publications

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 24, 2024
Similar Doctors
Advanced in Hydatidiform Mole
Dr. Albert J. Steren
Obstetrics and Gynecology | Oncology | Surgical Oncology
Advanced in Hydatidiform Mole
Dr. Albert J. Steren
Obstetrics and Gynecology | Oncology | Surgical Oncology

Maryland Oncology Hematology PA

9905 Medical Ctr Dr, Suite 300, 
Rockville, MD 
 (4.3 miles away)
240-487-7522
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Albert Steren is an Obstetrics and Gynecologist and an Oncologist in Rockville, Maryland. Dr. Steren is rated as a Distinguished provider by MediFind in the treatment of Hydatidiform Mole. His top areas of expertise are Endometrial Stromal Sarcoma, Uterine Fibroids, Endometrial Cancer, Hysterectomy, and Vaginectomy. Dr. Steren is currently accepting new patients.

Advanced in Hydatidiform Mole
Dr. Rebecca L. Stone
Obstetrics and Gynecology | Oncology | Gynecologic Oncology
Advanced in Hydatidiform Mole
Dr. Rebecca L. Stone
Obstetrics and Gynecology | Oncology | Gynecologic Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (33.3 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Stone is an Obstetrics and Gynecologist and an Oncologist in Baltimore, Maryland. Dr. Stone is rated as a Distinguished provider by MediFind in the treatment of Hydatidiform Mole. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ovarian Cancer, Oophorectomy, and Hernia Surgery. Dr. Stone is currently accepting new patients.

Experienced in Hydatidiform Mole
Dr. Dana M. Roque
Gynecologic Oncology | Obstetrics and Gynecology
Experienced in Hydatidiform Mole
Dr. Dana M. Roque
Gynecologic Oncology | Obstetrics and Gynecology

University Of Maryland Obstetrical And Gynecological Associates PA

419 W Redwood St, Suite 500, 
Baltimore, MD 
 (31.6 miles away)
410-328-6640
Languages Spoken:
English
See accepted insurances

Dana Roque is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Baltimore, Maryland. Dr. Roque is rated as a Distinguished provider by MediFind in the treatment of Hydatidiform Mole. Her top areas of expertise are Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Bladder Reconstruction, and Hernia Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barter's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile